tuberculosi
tb
global
public
health
threat
remain
major
caus
death
infecti
diseas
among
mani
risk
factor
activ
endstag
renal
diseas
esrd
requir
dialysi
recent
highlight
high
global
preval
condit
relat
increas
incid
diabet
age
popul
develop
develop
korea
confront
increas
popul
elderli
individu
patient
diabet
led
rapid
increas
number
patient
thu
converg
tb
esrd
epidem
gener
signific
public
health
burden
make
difficult
control
tb
korea
intermedi
tbrelat
burden
chronic
kidney
diseas
ckd
associ
alter
cellular
immun
caus
variou
factor
includ
advanc
age
uraemia
hypoalbuminemia
malnutrit
medic
immunosuppress
esrd
abnorm
function
monocyt
neutrophil
dendrit
cell
directli
link
risk
furthermor
ckd
link
condit
increas
risk
develop
activ
tb
diabet
transplant
human
immunodefici
viru
hiv
infect
moreov
dialysi
patient
esrd
frequent
expos
healthcar
set
suscept
nosocomi
infect
might
sourc
tb
transmiss
infecti
diseas
tb
attract
consider
public
attent
korea
sinc
middl
east
respiratori
syndrom
outbreak
involv
larg
number
suspect
hospitalacquir
tb
known
signific
threat
patient
receiv
dialysi
higher
tbrelat
mortal
rate
gener
popul
higher
rate
patient
receiv
dialysi
without
health
threat
tb
patient
esrd
attract
research
attent
sever
decad
howev
previou
studi
limit
small
number
patient
retrospect
propens
scorematch
cohort
studi
use
korean
nation
health
insur
data
examin
incid
activ
tb
larg
popul
patient
receiv
dialysi
well
esrdrel
risk
develop
activ
tb
dialysi
control
cohort
creat
use
korean
nation
health
insur
servic
knhi
databas
maintain
singl
nation
insur
provid
cover
korean
popul
data
regard
patient
receiv
dialysi
obtain
knhi
databas
contain
reimburs
data
medic
facil
fig
also
collect
control
data
knhisnat
sampl
cohort
nsc
includ
approxim
individu
total
korean
popul
creat
use
knhi
databas
use
public
health
research
polici
knhi
databas
contain
data
regard
patient
gender
age
incom
level
well
data
regard
medic
care
utilis
eg
date
treatment
diagnos
diseas
prescrib
drug
medic
surgic
procedur
patient
newli
diagnos
esrd
select
dialysi
cohort
case
dialysi
identifi
use
claim
procedur
materi
relat
haemodialysi
periton
dialysi
base
korean
electron
data
interchang
code
haemodialysi
periton
dialysi
patient
diagnosi
esrd
use
medic
servic
exclud
base
assumpt
chronic
esrd
patient
consid
elig
receiv
dialysi
day
small
portion
patient
might
receiv
renal
replac
therapi
acut
kidney
injuri
recov
suffici
renal
function
stop
dialysi
criteria
identifi
dialysi
use
exclud
patient
knhisnsc
receiv
dialysi
creat
control
cohort
present
studi
incid
activ
tb
dialysi
control
cohort
identifi
use
intern
classif
diseas
revis
code
diagnosi
activ
tb
confirm
base
prescript
antitb
drug
period
antitb
drug
includ
isoniazid
rifampicin
ethambutol
pyrazinamid
amikacin
kanamycin
streptomycin
quinolon
thioamid
cycloserin
paraaminosalicyl
acid
patient
diagnos
activ
tb
exclud
ensur
newli
diagnos
patient
tb
includ
factor
might
influenc
incid
activ
tb
gender
age
incom
level
comorbid
use
independ
variabl
data
regard
covari
avail
dialysi
control
cohort
use
knhi
databas
comorbid
identifi
base
code
diabet
mellitu
malign
chronic
obstruct
pulmonari
diseas
copd
hiv
infect
silicosi
incom
level
score
scale
categoris
three
group
low
middl
high
includ
patient
began
dialysi
diagnosi
activ
tb
base
visit
date
wash
data
ensur
newli
diagnos
patient
esrd
includ
data
exclud
knhisnsc
databas
contain
data
final
elig
patient
start
dialysi
dialysi
cohort
identifi
exclud
potenti
preexist
case
dialysi
activ
tb
identifi
individu
without
esrd
knhisnsc
databas
control
cohort
propens
score
match
equal
number
esrd
case
propens
score
match
use
nearest
neighbour
method
perform
identifi
similar
individu
dialysi
control
cohort
use
matchlt
packag
version
r
softwar
version
r
foundat
statist
comput
vienna
austria
logist
regress
use
creat
propens
score
patient
base
age
gender
incom
level
comorbid
individu
cohort
randomli
order
match
use
nearest
neighbour
method
match
algorithm
identifi
uniqu
match
control
individu
dialysi
cohort
accord
propens
score
match
complet
match
consid
match
could
found
algorithm
proceed
sequenti
individu
closest
propens
score
make
nextbest
match
improv
generalis
reduc
potenti
bia
caus
incomplet
match
use
random
select
sampl
set
proport
differ
independ
variabl
esrd
control
cohort
analys
use
wald
test
incid
activ
tb
express
number
newli
diagnos
activ
tb
case
per
personyear
incid
rate
ratio
irr
esrd
rel
control
calcul
confid
interv
ci
use
epir
packag
version
r
softwar
version
r
foundat
statist
comput
appli
multivari
cox
proport
hazard
model
independ
variabl
combin
two
cohort
determin
esrdrel
risk
develop
activ
tb
report
hazard
ratio
hr
ci
evalu
proport
hazard
assumpt
test
signific
timedepend
interact
term
variabl
found
satisfactori
cumul
tb
incid
curv
gener
use
kaplanmei
method
differ
two
cohort
analys
use
logrank
test
followup
period
start
first
date
dialysi
case
randomli
select
visit
date
control
correspond
calendar
year
match
start
dialysi
case
followup
period
end
first
date
tb
diagnosi
last
followup
date
analys
perform
use
sa
softwar
version
sa
institut
inc
cari
nc
usa
r
softwar
version
r
foundat
statist
comput
studi
retrospect
protocol
approv
institut
review
board
irb
chungbuk
nation
univers
hospit
korea
irb
patient
record
previous
anonymis
ensur
patient
confidenti
search
knhi
databas
identifi
patient
newli
diagnos
esrd
dialysi
cohort
correspond
number
individu
select
control
cohort
individu
characterist
summaris
tabl
individu
match
result
compar
distribut
age
gender
household
incom
comorbid
dialysi
control
cohort
observ
period
personyear
dialysi
cohort
personyear
control
cohort
mean
durat
followup
year
dialysi
cohort
year
control
cohort
newli
diagnos
activ
tb
detect
patient
dialysi
cohort
individu
control
cohort
tabl
incid
personyear
dialysi
cohort
personyear
control
cohort
compar
control
patient
esrd
significantli
elev
risk
activ
tb
irr
ci
subgroup
analys
reveal
similarli
elev
risk
activ
tb
among
patient
esrd
subgroup
except
year
age
group
averag
interv
initi
enrol
diagnosi
activ
tb
year
year
dialysi
cohort
year
control
cohort
cumul
activ
tb
incid
significantli
higher
dialysi
cohort
control
cohort
p
logrank
test
fig
subgroup
analys
reveal
similar
result
haemodialysi
periton
dialysi
p
logrank
test
howev
signific
differ
risk
activ
tb
haemodialysi
periton
dialysi
subgroup
p
logrank
test
multivari
cox
proport
hazard
analysi
reveal
patient
receiv
dialysi
esrd
independ
elev
risk
activ
tb
adjust
hr
ci
tabl
addit
elev
risk
activ
tb
independ
associ
haemodialysi
adjust
hr
ci
periton
dialysi
adjust
hr
ci
tabl
analysi
reveal
signific
risk
factor
nationwid
cohort
studi
reveal
dialysi
associ
higher
risk
activ
tb
among
match
control
group
best
knowledg
largest
studi
investig
risk
develop
activ
tb
start
dialysi
esrd
howev
result
consist
previou
report
describ
high
risk
activ
tb
among
patient
esrd
exampl
one
nationwid
cohort
studi
countri
low
incid
includ
patient
receiv
dialysi
esrd
reveal
overal
incid
activ
tb
personyear
recent
also
estim
dialysi
associ
pool
unadjust
rate
ratio
ci
although
numer
studi
investig
relationship
activ
tb
ckd
previou
studi
case
report
casecontrol
studi
small
hospitalbas
cohort
studi
region
registri
recent
taiwanes
includ
patient
newonset
esrd
age
gendermatch
control
group
reveal
esrd
associ
higher
risk
develop
activ
tb
present
studi
also
examin
larg
populationbas
sampl
individu
receiv
dialysi
comparison
match
control
group
reveal
relationship
activ
tb
esrd
addit
mortal
morbid
sever
issu
burden
relat
tb
highlight
among
patient
esrd
exampl
clinic
manifest
activ
tb
dialysi
often
insidi
patient
esrd
tb
frequent
present
system
symptom
similar
uraemia
delay
diagnosi
patient
may
also
present
extrapulmonari
dissemin
among
patient
ckd
standard
antitb
treatment
involv
quadrupl
therapi
although
problemat
ethambutol
pyrazinamid
clear
kidney
requir
renaladjust
dose
addit
rifampicin
often
interact
antihypertens
antidiabet
immunosuppress
medic
necessit
dose
furthermor
antitb
medic
caus
sever
frequent
toxic
among
patient
esrd
includ
gastrointestin
troubl
decreas
appetit
limit
treatment
regimen
screen
latent
activ
tb
infect
among
patient
esrd
anoth
import
issu
control
tb
although
world
health
organ
recommend
system
test
tb
among
patient
receiv
dialysi
transplant
pauciti
evid
guid
screen
recommend
optim
treatment
latent
tb
infect
unclear
among
patient
advanc
ckd
thu
need
clear
consist
guidanc
develop
suitabl
protocol
screen
diagnosi
treatment
tb
among
patient
ckd
haemodialysi
periton
dialysi
associ
increas
risk
activ
tb
present
studi
modal
share
risk
associ
acquir
immunodefici
due
uraemia
two
previou
studi
evalu
risk
activ
tb
among
patient
undergo
periton
dialysi
reveal
higher
preval
tb
popul
among
gener
although
patient
undergo
haemodialysi
markedli
frequent
hospit
visit
undergo
periton
dialysi
risk
tb
differ
present
studi
consist
result
previou
therefor
specul
risk
nosocomi
tb
infect
great
concern
among
patient
undergo
dialysi
sever
wellknown
comorbid
associ
risk
activ
subanalys
patient
diabet
malign
copd
also
increas
rate
ratio
activ
tb
although
multivari
analysi
reveal
associ
comorbid
tb
insignific
hypothesis
uraemiarel
risk
infect
strong
enough
outweigh
influenc
condit
addit
hiv
infect
anoth
import
risk
factor
activ
tb
although
preval
hiv
infect
low
identifi
one
case
activ
tb
among
patient
hiv
infect
esrd
indic
hiv
infect
statu
like
confound
relationship
dialysi
tb
present
studi
sever
limit
consid
first
studi
collect
data
base
diagnost
code
insur
claim
preclud
analysi
inform
regard
lifestyl
clinic
variabl
could
influenc
risk
tb
infect
attempt
control
confound
use
avail
data
exampl
includ
copd
adjust
effect
smoke
copd
mainli
attribut
also
includ
household
incom
repres
variou
factor
associ
socioeconom
statu
histori
antitb
treatment
studi
enrol
exclud
order
minimis
effect
recent
tb
infect
although
use
immunosuppress
drug
import
risk
factor
activ
tb
develop
dialysi
patient
rare
use
immunosuppress
clinic
practic
dialysi
also
suppress
patient
immun
thu
base
limit
use
elect
omit
immunosuppress
use
covari
second
dialysi
patient
might
frequent
visit
clinic
higher
likelihood
receiv
appropri
screen
eg
chest
radiographi
would
like
seek
medic
attent
tb
symptom
aros
thu
ascertain
detect
bias
might
contribut
higher
rate
activ
tb
identif
dialysi
cohort
control
cohort
nevertheless
korea
singl
nation
health
insur
servic
ensur
citizen
easi
inexpens
access
medic
care
nation
health
screen
program
provid
regular
chest
radiographi
examin
everi
healthi
frequent
lead
earli
diagnosi
activ
tb
thu
although
might
delay
control
cohort
tb
diagnosi
suspect
underestim
activ
tb
identif
cohort
would
minim
third
diagnosi
activ
tb
base
code
drug
prescript
histori
may
associ
limit
sensit
diagnos
tb
specif
combin
antitb
drug
might
accur
drug
may
prescrib
infecti
diseas
nontubercul
mycobacteria
diseas
recent
show
patient
mycobacterium
avium
complex
lung
diseas
transient
receiv
antitb
treatment
final
diagnosi
howev
criterion
use
variou
previou
studi
metaanalys
korean
law
requir
activ
tb
case
report
use
code
assum
use
code
valid
reliabl
approach
despit
limit
major
strength
present
studi
larg
sampl
size
increas
result
statist
power
accuraci
provid
better
generalis
furthermor
dialysi
cohort
creat
use
patient
nephrologistconfirm
diagnosi
esrd
cohort
design
epidemiologist
final
prolong
followup
suffici
examin
tempor
relationship
onset
esrd
subsequ
activ
tb
conclus
present
studi
reveal
epidemiolog
evid
receiv
dialysi
esrd
associ
increas
risk
develop
activ
tb
although
accumul
evid
regard
effect
tb
esrd
public
health
intern
societi
recent
recommend
systemat
tb
test
patient
receiv
dialysi
current
guidelin
still
therefor
remain
need
detail
wellorganis
guidelin
identif
activ
tb
case
among
patient
esrd
